Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary
- Author
- BONGARTZ, Tim (Commentator (written text))
1 ; SMOLEN, Josef S2 3 ; BEAULIEU, Andre4 ; RUBBERT-ROTH, Andrea5 ; RAMOS-REMUS, Cesar6 ; ROVENSKY, Josef7 ; ALECOCK, Emma8 ; WOODWORTH, Thasia8 ; ALTEN, Rieke9
[1] Department of Internal Medicine and Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States
[2] Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
[3] 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
[4] Faculty of Medicine, Laval University, Laval, Quebec, Canada
[5] Medical Clinic I, university of Cologne, Cologne, Germany
[6] Research Unit for Chronic Diseases, Guadalajara, Mexico
[7] National Institute of Rheumatic Diseases, Piestany, Slovakia
[8] Roche Products Ltd, Welwyn, United Kingdom
[9] Department of Internal Medicine II, Rheumatology, Schlosspark Clinic, University Medicine Berlin, Berlin, Germany
OPTION Investigators - Source
Lancet (British edition). 2008, Vol 371, Num 9617 ; 961-963, 987-997 [14 p.] ; ref : 62 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Lancet, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Chronique Etude double insu Homme Immunomodulateur Inhibition Interleukine 6 Malade Médecine Polyarthrite rhumatoïde Randomisation Tocilizumab Anticorps monoclonal Cytokine Immunopathologie Maladie autoimmune Pathologie du système ostéoarticulaire Rhumatisme inflammatoire
- Keyword (en)
- Chronic Double blind study Human Immunomodulator Inhibition Interleukin 6 Patient Medicine Rheumatoid arthritis Randomization Tocilizumab Monoclonal antibody Cytokine Immunopathology Autoimmune disease Diseases of the osteoarticular system Inflammatory joint disease
- Keyword (es)
- Crónico Estudio doble ciego Hombre Inmunomodulador Inhibición Interleuquina 6 Enfermo Medicina Poliartritis reumatoidea Aleatorización Tocilizumab Anticuerpo monoclonal Citoquina Inmunopatología Enfermedad autoinmune Sistema osteoarticular patología Reumatismo inflamatorio
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B15 Diseases of the osteoarticular system / 002B15D Inflammatory joint diseases
- Discipline
- Generalities in medical sciences Osteoarticular pathology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20204643
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"371\";s:8:\"\u0000*\u0000issue\";s:4:\"9617\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:24:\"961-963, 987-997 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BONGARTZ\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Tim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"SMOLEN, Josef S\";i:1;s:15:\"BEAULIEU, Andre\";i:2;s:20:\"RUBBERT-ROTH, Andrea\";i:3;s:18:\"RAMOS-REMUS, Cesar\";i:4;s:15:\"ROVENSKY, Josef\";i:5;s:13:\"ALECOCK, Emma\";i:6;s:17:\"WOODWORTH, Thasia\";i:7;s:12:\"ALTEN, Rieke\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Lancet\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"371\";s:8:\"\u0000*\u0000issue\";s:4:\"9617\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:24:\"961-963, 987-997 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BONGARTZ\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Tim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"SMOLEN, Josef S\";i:1;s:15:\"BEAULIEU, Andre\";i:2;s:20:\"RUBBERT-ROTH, Andrea\";i:3;s:18:\"RAMOS-REMUS, Cesar\";i:4;s:15:\"ROVENSKY, Josef\";i:5;s:13:\"ALECOCK, Emma\";i:6;s:17:\"WOODWORTH, Thasia\";i:7;s:12:\"ALTEN, Rieke\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Lancet\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"371\";s:8:\"\u0000*\u0000issue\";s:4:\"9617\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:24:\"961-963, 987-997 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BONGARTZ\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Tim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"SMOLEN, Josef S\";i:1;s:15:\"BEAULIEU, Andre\";i:2;s:20:\"RUBBERT-ROTH, Andrea\";i:3;s:18:\"RAMOS-REMUS, Cesar\";i:4;s:15:\"ROVENSKY, Josef\";i:5;s:13:\"ALECOCK, Emma\";i:6;s:17:\"WOODWORTH, Thasia\";i:7;s:12:\"ALTEN, Rieke\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Lancet\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"371\";s:8:\"\u0000*\u0000issue\";s:4:\"9617\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:24:\"961-963, 987-997 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BONGARTZ\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Tim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"SMOLEN, Josef S\";i:1;s:15:\"BEAULIEU, Andre\";i:2;s:20:\"RUBBERT-ROTH, Andrea\";i:3;s:18:\"RAMOS-REMUS, Cesar\";i:4;s:15:\"ROVENSKY, Josef\";i:5;s:13:\"ALECOCK, Emma\";i:6;s:17:\"WOODWORTH, Thasia\";i:7;s:12:\"ALTEN, Rieke\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Lancet\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"371\";s:8:\"\u0000*\u0000issue\";s:4:\"9617\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:24:\"961-963, 987-997 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BONGARTZ\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Tim\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"SMOLEN, Josef S\";i:1;s:15:\"BEAULIEU, Andre\";i:2;s:20:\"RUBBERT-ROTH, Andrea\";i:3;s:18:\"RAMOS-REMUS, Cesar\";i:4;s:15:\"ROVENSKY, Josef\";i:5;s:13:\"ALECOCK, Emma\";i:6;s:17:\"WOODWORTH, Thasia\";i:7;s:12:\"ALTEN, Rieke\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:180:\"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Lancet\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
